Smith & Nephew SNATS (NYSE:SNN – Get Free Report) was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Saturday.
Several other research analysts have also commented on the company. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Monday, April 20th. Canaccord Genuity Group set a $32.00 price target on Smith & Nephew SNATS in a research report on Friday, April 24th. One investment analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $34.75.
Read Our Latest Stock Report on Smith & Nephew SNATS
Smith & Nephew SNATS Trading Down 0.2%
Smith & Nephew SNATS (NYSE:SNN – Get Free Report) last posted its earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share (EPS) for the quarter. The business had revenue of $1.60 billion for the quarter. Analysts predict that Smith & Nephew SNATS will post 2.29 EPS for the current fiscal year.
Institutional Trading of Smith & Nephew SNATS
A number of institutional investors have recently bought and sold shares of SNN. Paradigm Asset Management Co. LLC acquired a new stake in shares of Smith & Nephew SNATS during the third quarter worth about $1,502,000. Todd Asset Management LLC acquired a new stake in shares of Smith & Nephew SNATS during the third quarter worth about $26,319,000. Citigroup Inc. increased its position in shares of Smith & Nephew SNATS by 44.8% during the third quarter. Citigroup Inc. now owns 486,661 shares of the medical equipment provider’s stock worth $17,661,000 after purchasing an additional 150,517 shares in the last quarter. Factory Mutual Insurance Co. acquired a new stake in shares of Smith & Nephew SNATS during the third quarter worth about $1,007,000. Finally, Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Smith & Nephew SNATS during the third quarter worth about $16,501,000. 25.64% of the stock is owned by hedge funds and other institutional investors.
About Smith & Nephew SNATS
Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.
In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.
Read More
- Five stocks we like better than Smith & Nephew SNATS
- Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum
- Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players
- Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery
- 3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill
Receive News & Ratings for Smith & Nephew SNATS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS and related companies with MarketBeat.com's FREE daily email newsletter.
